PFBT
ORIC icon

Parkside Financial Bank & Trust’s Oric Pharmaceuticals ORIC Stock Holding History

Parkside Financial Bank & Trust’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$279 – 2926
2025
Q1 		$279 Buy
+50
New +$437 ﹤0.01% 2644

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Parkside Financial Bank & Trust's ORIC Position: Q2 2025 in Review

Parkside Financial Bank & Trust sold out of Oric Pharmaceuticals (ORIC) in Q2 2025, closing a stake of 50 shares — an estimated $279 sold.

Parkside Financial Bank & Trust first reported a position in ORIC in Q1 2025 and held it in 1 quarter. The position peaked at $279 in Q1 2025. 142 funds tracked by Wall St. Rank hold ORIC as of Q2 2025.

  • Parkside Financial Bank & Trust reported no remaining Oric Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 50 Oric Pharmaceuticals shares in Q2 2025, an estimated $279.
  • Parkside Financial Bank & Trust first reported a position in Oric Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Parkside Financial Bank & Trust's Oric Pharmaceuticals position peaked at $279 in Q1 2025.
  • 142 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2025, filed 7 Aug 2025.